Akorn develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the United States and internationally.

According to the law firm press release , the lawsuit alleges that Defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius's acquisition of Akorn; (2) Akorn lacked effective internal controls over financial reporting; and (3) as a result, Akorn's financial statements were materially false and misleading at all relevant times.